MX2010009344A - Preparacion de lenalidomida. - Google Patents

Preparacion de lenalidomida.

Info

Publication number
MX2010009344A
MX2010009344A MX2010009344A MX2010009344A MX2010009344A MX 2010009344 A MX2010009344 A MX 2010009344A MX 2010009344 A MX2010009344 A MX 2010009344A MX 2010009344 A MX2010009344 A MX 2010009344A MX 2010009344 A MX2010009344 A MX 2010009344A
Authority
MX
Mexico
Prior art keywords
lenalidomide
preparation
substantially pure
pure
enriched
Prior art date
Application number
MX2010009344A
Other languages
English (en)
Inventor
Veerender Murki
Surya Narayana Devarakonda
Vamsi Krishna Mudapaka
Sesha Reddy Yarraguntla
Venu Nalivela
Rajasekhar Kadaboina
Amarendhar Manda
Rama Seshagiri Rao Pulla
Venkata Rao Badisa
Naresh Vemula
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN605CH2008 priority Critical
Priority to US5371008P priority
Priority to IN1422CH2008 priority
Priority to US10010608P priority
Priority to IN2866CH2008 priority
Priority to US14396609P priority
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Priority to PCT/US2009/036773 priority patent/WO2009114601A2/en
Publication of MX2010009344A publication Critical patent/MX2010009344A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1

Abstract

Se describen los procesos para la preparación de lenalidomida prácticamente pura. La solicitud también se relaciona con una forma amorfa enriquecida prácticamente pura y pura de lenalidomida y las dispersiones sólidas que contienen lenalidomida amorfa.
MX2010009344A 2008-03-11 2009-03-11 Preparacion de lenalidomida. MX2010009344A (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IN605CH2008 2008-03-11
US5371008P true 2008-05-16 2008-05-16
IN1422CH2008 2008-06-11
US10010608P true 2008-09-25 2008-09-25
IN2866CH2008 2008-11-19
US14396609P true 2009-01-12 2009-01-12
PCT/US2009/036773 WO2009114601A2 (en) 2008-03-11 2009-03-11 Preparation of lenalidomide

Publications (1)

Publication Number Publication Date
MX2010009344A true MX2010009344A (es) 2012-09-28

Family

ID=41065812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009344A MX2010009344A (es) 2008-03-11 2009-03-11 Preparacion de lenalidomida.

Country Status (12)

Country Link
US (2) US20110021567A1 (es)
EP (1) EP2262768A4 (es)
JP (1) JP2011513497A (es)
KR (1) KR20100124710A (es)
CN (1) CN101959856A (es)
AU (1) AU2009223014A1 (es)
CA (1) CA2717326C (es)
EA (1) EA201071058A1 (es)
IL (1) IL207993D0 (es)
MX (1) MX2010009344A (es)
WO (1) WO2009114601A2 (es)
ZA (1) ZA201006252B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041282T2 (hu) 2003-09-04 2019-05-28 Celgene Corp A 3-(4-amino-1-oxo-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion polimorf formái
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PL2380887T3 (pl) 2005-06-30 2014-01-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
WO2010056384A1 (en) * 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
AU2010220204B2 (en) 2009-03-02 2015-10-08 Generics [Uk] Limited Improved process
EP2464638A1 (en) * 2009-08-12 2012-06-20 Synthon B.V. Lenalidomide salts
EP2493872A1 (en) * 2009-09-03 2012-09-05 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
WO2011061611A1 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2011064574A1 (en) * 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011069608A1 (en) * 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体Ⅳ及其药用组合物
KR20130038232A (ko) 2010-03-08 2013-04-17 낫코 파마 리미티드 무수 레날리도마이드 form-i
CN102453020A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 一种来那度胺的新晶型及其制备方法
EP2688649B1 (en) * 2011-03-23 2019-04-10 Hetero Research Foundation A polymorph of lenalidomide
WO2014066243A1 (en) * 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014121033A1 (en) 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
CN103497175B (zh) * 2013-03-14 2015-08-05 湖北生物医药产业技术研究院有限公司 制备来那度胺的方法
CN103193763B (zh) * 2013-04-10 2015-09-16 杭州百诚医药科技有限公司 一种来那度胺的制备方法
CN103421061A (zh) * 2013-08-14 2013-12-04 中国药科大学 来那度胺衍生物、其制法及其医药用途
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
EP2875817A1 (en) * 2013-11-26 2015-05-27 Synhton B.V. Pharmaceutical formulation comprising amorphous lenalidomide
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
WO2015200837A1 (en) 2014-06-27 2015-12-30 Fl Therapeutics Llc Abiraterone derivatives and non-covalent complexes with albumin
WO2016024286A2 (en) 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
US10201617B2 (en) 2014-10-24 2019-02-12 Zhuhai Beihai Biotech Co., Ltd. 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
US10471156B2 (en) 2014-12-19 2019-11-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
US10507204B2 (en) 2014-12-19 2019-12-17 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
WO2017109041A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
TWI664172B (zh) * 2016-08-25 2019-07-01 大陸商浙江海正藥業股份有限公司 來那度胺的晶型及其製備方法和用途
CN107400115A (zh) * 2017-08-04 2017-11-28 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
WO2019092752A2 (en) * 2017-11-13 2019-05-16 Avra Laboratories Pvt. Ltd. Novel salt of lenalidomide and polymorphic forms thereof
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
CN109608434A (zh) * 2018-12-27 2019-04-12 浙江工业大学 一种来那度胺的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928231A (en) * 1972-10-06 1975-12-23 Us Agriculture Selective hydrocarboxylation of unsaturated fatty compounds
JPH08208476A (ja) * 1995-02-01 1996-08-13 Kanebo Ltd ニフェジピン含有持続性製剤
AT240734T (de) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CA2261762C (en) * 1996-07-24 2008-06-17 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
AU2002323063B2 (en) * 2001-08-06 2007-11-08 Entremed, Inc. Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
HUE041282T2 (hu) * 2003-09-04 2019-05-28 Celgene Corp A 3-(4-amino-1-oxo-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion polimorf formái
WO2005099677A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene acetate solid dispersion formulations
ES2437592T3 (es) * 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
EA015715B1 (ru) * 2005-08-29 2011-10-31 САНОФИ-АВЕНТИС Ю. Эс. ЭлЭлСи Твердая дисперсия, фармацевтическая композиция, включающая такую дисперсию, способ ее получения и применение для предотвращения и лечения заболеваний, связанных с бензодиазепиновыми рецепторами периферического типа
US20110064811A1 (en) * 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
EP2464638A1 (en) * 2009-08-12 2012-06-20 Synthon B.V. Lenalidomide salts

Also Published As

Publication number Publication date
IL207993D0 (en) 2010-12-30
CA2717326A1 (en) 2009-09-17
WO2009114601A2 (en) 2009-09-17
JP2011513497A (ja) 2011-04-28
EP2262768A2 (en) 2010-12-22
AU2009223014A1 (en) 2009-09-17
EP2262768A4 (en) 2011-03-23
US20160194301A1 (en) 2016-07-07
ZA201006252B (en) 2011-06-29
WO2009114601A3 (en) 2009-12-03
CN101959856A (zh) 2011-01-26
KR20100124710A (ko) 2010-11-29
CA2717326C (en) 2018-10-23
US20110021567A1 (en) 2011-01-27
EA201071058A1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
PH12013502230A1 (en) Multispecific antibodies
HK1201274A1 (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof 33- 19-
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
PH12014501786A1 (en) Compounds for treating spinal muscular atrophy
MX2014007024A (es) Anticuerpos contra csf-1r humano y sus usos.
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
IL227815D0 (en) Pyrrolopyrazine-spirocyclic piperidine amide compounds, compositions comprising the same and uses thereof
WO2012061603A3 (en) Compositions comprising and methods for forming functionalized carbon-based nanostructures
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
HK1162455A1 (zh) 尾礦流的處理
PH12015501483B1 (en) Heterocyclic compounds and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2012012872A (es) Procedimiento para preparar ditiin-tetracarboxi-diimidas.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
MX2012014431A (es) Modulares del receptor de estrogenos y usos de los mismos.
MX2013015317A (es) Composiciones pesticidas y procedimientos relacionados con estas.
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
WO2012068105A3 (en) Compositions and uses thereof in converting contaminants
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
CR20130184A (es) Composiciones bioactivas de chromobacterium y metabolitos
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
WO2011107186A3 (de) Verbindungen für elektronische vorrichtungen
SG175080A1 (en) Bispecific anti-erbb-2/anti-c-met antibodies
WO2012006440A3 (en) Endothelial cell production by programming

Legal Events

Date Code Title Description
FC Refusal